Thymoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
VIP Variant #01 | — | R 10 535 | 21d | — | — | — | — | — |
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | ~5.4 mo | ~11.0 mo | ~8 | ~R 40 246 PFS proxy · indirect | 57 |
Cisplatin and Etoposide (EP) Variant #01 | — | R 4 264 | 42d | ~5.0 mo | ~10.0 mo | ~4 | ~R 17 056 PFS proxy · indirect | 11 |
ADOC Variant #01 | — | R 883 | 28d | — | — | — | — | — |
CISCA Variant #02 | — | R 678 | 21d | — | — | — | — | — |
5 of 5 regimens shown